Nov 7 (Reuters) - SENSORION SA ALSEN.PA :
* SENSORION ANNOUNCES PRESENTATION OF SENS-401 POSTER AT
SOCIETY
FOR NEUROSCIENCE 2018 ANNUAL MEETING
* PRECLINICAL DATA SUGGEST EFFICACY OF SENS-401 IS NOT
AFFECTED BY
CONCOMITANT ADMINISTRATION OF A CORTICOSTEROID
* ADDS TO EVIDENCE SUPPORTING USE OF SENS-401 IN SUDDEN
SENSORINEURAL HEARING LOSS (SSNHL)
* PHASE II TRIAL OF SENS-401 IN SSNHL IS ONGOING
Source text for Eikon: ID:nBw4t3dpTa
Further company coverage: ALSEN.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))